TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Change in perceived/subjective relaxation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Detection of thyroid cancer using ctDNA measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Area under the plasma concentration time curve extrapolated to infinity (AUC0-∞)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Apparent terminal elimination half-life (t1/2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Discrimination of Barrett's Esophagus tissue from other tissue types
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Changes of Coronary Flow Reserve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: number of participants with postoperative complications
Endpoint domain: Adverse events/effects
Primary endpoint: arterial blood pH values in the first 24 hours postoperatively
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Plasma concentrations of INS37217
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in total weekly minutes of physical activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean cumulative irritation score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total cumulative irritation score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perceived Relaxation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Fingertip Temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage of patients with stable HbA1c
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: mean change in forced expiratory volume in one second
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Days to medical clearance to return to sport
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Accuracy of the Pitching Detection Algorithm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence or absence of intra labyrinthine vestibular nerve tumor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Changes in renal resistive index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Positioning pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Energy expenditure during physical activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Humoral Immune Response for Each Vaccine Strain in Terms of Haemagglutination Inhibition (HI) Antibody Titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Seropositive Subjects for HI Antibodies Against Each of the 4 Vaccine Strains
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Subjects Who Were Seroprotected for Anti-HI Antibodies Against Each of the 4 Vaccine Influenza Strains
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: MACE within 2 weeks
Endpoint domain: Mortality/survival
Primary endpoint: MACE within 1 year
Endpoint domain: Mortality/survival
Primary endpoint: residual shunt at 6-12 months follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: stroke recurrence
Endpoint domain: Mortality/survival
Primary endpoint: Changes in muscle strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Comparison of muscle mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Self sufficiency
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Serious Quit Attempt
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Tumor Proliferation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Final diagnosis accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Percent change from baseline in calculated LDL-C
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Occurrence of Recurrent Pericarditis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: change of quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Number of Subjects Who Achieved Complete Remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Skin circulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Time course of FGF23 (c-terminal)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Time course of FGF23 (intact)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Number of Participants Achieving Treatment Success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mobile Asthma Action Plan Usage
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: immunogenicity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Rate of successful biopsies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Ventilator free-days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Time-up and go test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oseltamivir pharmacokinetic parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oseltamivir carboxylate pharmacokinetic parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: residual stone rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Open Surgery Outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Endovascular Repair Outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Incidence of Treatment-emergent Adverse Events (TEAEs) and Serious AEs (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Area under the concentration-time curve AUC (tau)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjective Alertness via Karolinska Sleepiness Scale (KSS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: safety and efficacy of bee venom maintenance dose
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of dose-limiting toxicities during study treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of dose-limiting toxicities during study follow-up
Endpoint domain: Adverse events/effects
Primary endpoint: Anti-PRAME humoral immune response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: chest wall and lung compliance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: SiSBP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants With Complete Response (CR) or Partial Response (PR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Complete Response (CR) or Partial Response (PR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Insomnia Clinical Diagnosis Over Time
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Change in Patient Health Questionnaire-9 (PHQ-9) Scale Score as a Measure of Depression Symptoms Over Time
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Generalized Anxiety Disorder-7 (GAD-7) Scale Score Over Time
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Maximal Oxygen Uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stationary Oxygen Use Daily
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Ambulatory/Portable Oxygen Use Daily
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Risk of Acute Urinary Retention and Surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Quantitative absorption of chlorogenic acids metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mass balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in caregiver well-being
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of Successful Glucose Readings
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: BOLD fMRI response during emotion processing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage of Participants Experiencing at Least One Treatment-Emergent Adverse Event (TEAE)
Endpoint domain: Adverse events/effects
Primary endpoint: 75% Responder Rate by 3-month Interval
Endpoint domain: Adverse events/effects
Primary endpoint: Net Incremental Area Under the Curve (niAUC) of Perceived Hunger and Fullness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Net Incremental Area Under the Curve (niAUC) of Plasma Total Glucagon-like Peptide (GLP-1) and Total Peptide YY (PYY)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: glycemic qualification rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Lipoprotein production and clearance rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Esophageal Pressure Time Product per minute (PTPes.min)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of dysthyroidism post-RI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Efficacy of whole body cryotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Humoral and Cellular Immune Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: rate of obtaining potentially competent oocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Proportion of patients reaching minimal manifestation state
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: successful detection of pathogen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Percentage of Participants With Dose Limiting Toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Treatment Emergent Adverse Events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Disease Control Rate (DCR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: current clinical condition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline Self-determination after 20 sessions (Quantitative measure: self-report)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Self-determination (Qualitative measure)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change from baseline Self-determination after 20 sessions (Quantitative measure: proxy-report)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Response rate (CR/PR or SD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Coefficient of variation of erythrocyte fatty-acid parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: rSO2 level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: heart rate (min)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SpO2 level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neonates COMFORTneo scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: respiratory rate (min)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fastest Walking Speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effectiveness of Ondansetron vs Metoclopramide for nausea and vomiting
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of Visual Analysis Scale on Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Potential lung recruitment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Reduction of nitric oxide usage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Safety indexes of solicited and unsolicited adverse reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Safety indexes of lab measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gleason Grade
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Acute postoperative pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete eradication of all intestinal metaplasia (CEIM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Complete eradication of dysplasia (CED)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Incidence of CryoBalloon-related serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: failure rate (progression or death)
Endpoint domain: Mortality/survival
Primary endpoint: Infection or colonization with MDRO
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Maximum effect (Emax) of the Drug Liking VAS
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Presence of intra-uterine adhesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Number of patients with dose-limiting toxicity or therapy delay
Endpoint domain: Adverse events/effects
Primary endpoint: Glycemic disorders
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change of synechiae
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TAPSE (tricuspid annular plane systolic excursion)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change of endothelial function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Ramsay Sedation score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to Ramsay sedation score of 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Percentage Decrease in FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Time-Adjusted Area Under the Curve for Percent Decrease in FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Short Term Feasibility Success
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Long Term Feasibility Success
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Weekly rate of children's active commuting to school
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Changes in Adport Sandoz© trough level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Drain bulb fluid bacterial colonization
Endpoint domain: Adverse events/effects
Primary endpoint: Drain tip bacterial colonization
Endpoint domain: Adverse events/effects
Primary endpoint: Breast ultrasonography findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Best Overall Response (CR or PR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in immune response after revaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in 24-hour average systolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Strictures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neuropsychological assessment scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Local and systemic reactions to vaccine
Endpoint domain: Adverse events/effects
Primary endpoint: Adverse and serious adverse experiences
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum Tolerated Dose (MTD) of oxaliplatin
Endpoint domain: Adverse events/effects
Endpoint subdomain: Any subdomain
Primary endpoint: Incidence of Dose Limiting Toxicity (DLT)
Endpoint domain: Adverse events/effects
Endpoint subdomain: Any subdomain
Primary endpoint: Frequency of photoallergic and allergic reactions
Endpoint domain: Adverse events/effects
Primary endpoint: TxB2 formation in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Prostacyclin metabolite (PGI-M) formation in urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Biochemical selectivity for COX-2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with dyspeptic symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of participants with typical GERD symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Presence of individual symptoms of depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence of self-injection
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Area under the concentration-time curve (AUC(0-Tau))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Terminal phase half-life (T1/2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Depressive symptom status
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Recurrence free time
Endpoint domain: Mortality/survival
Primary endpoint: Objective refraction difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hypercapnic Ventilatory Response (HCVR) gradient
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Pain Score 1-hour
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in glycosylated hemoglobin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Onset of claudication pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Wrist muscle strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in hemoglobin A1c (HbA1c) level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Collagen mRNA levels in the skin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: In vivo collagen production
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline fecal microbiota profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in score on Walking Impairment Questionnaire (WIQ)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC[0-inf])
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in admissions and re-admissions
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Length of hospitalisation related to COPD
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Excessive bleeding during debridement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levels of bacterial load in debrided wounds
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: 6 month incidence of HF related Hospitalizations
Endpoint domain: Mortality/survival
Primary endpoint: Action potentials (mV) from peripheral nerves
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in AIMS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Number of Participants Who Needed Transfusions
Endpoint domain: Adverse events/effects
Primary endpoint: Cmax: Maximum Observed Plasma Concentration for ritonavir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC(0-inf): Area Under the Plasma Concentration-time Curve from Time 0 to Infinity for ritonavir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC(0-36h): Area Under the Plasma Concentration-Time Curve From Time 0 to 36 hours Postdose for ritonavir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes